Cargando…
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
BACKGROUND: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately, artesunate became available in the Netherlands and Belgium through a named patient pr...
Autores principales: | Kreeftmeijer-Vegter, Annemarie R, van Genderen, Perry J, Visser, Leo G, Bierman, Wouter FW, Clerinx, Jan, van Veldhuizen, Cees KW, de Vries, Peter J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364861/ https://www.ncbi.nlm.nih.gov/pubmed/22462806 http://dx.doi.org/10.1186/1475-2875-11-102 |
Ejemplares similares
-
Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2013) -
Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria
por: Kreeftmeijer-Vegter, Annemarie R, et al.
Publicado: (2013) -
The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014) -
Increase in imported malaria in the Netherlands in asylum seekers and VFR travellers
por: de Gier, Brechje, et al.
Publicado: (2017) -
Declining incidence of imported malaria in the Netherlands, 2000-2007
por: van Rijckevorsel, Gini GC, et al.
Publicado: (2010)